Compare ARTW & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARTW | HSCS |
|---|---|---|
| Founded | 1956 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3M | 15.8M |
| IPO Year | 1996 | 2022 |
| Metric | ARTW | HSCS |
|---|---|---|
| Price | $2.90 | $2.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.6K | ★ 80.3K |
| Earning Date | 10-09-2026 | 12-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 233.33 | 50.84 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $22,975,408.00 | $4,319.00 |
| Revenue This Year | N/A | $295.93 |
| Revenue Next Year | N/A | $18,321.05 |
| P/E Ratio | $73.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.05 | $1.63 |
| 52 Week High | $4.17 | $5.25 |
| Indicator | ARTW | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 35.12 |
| Support Level | $2.53 | $1.84 |
| Resistance Level | $2.96 | $2.76 |
| Average True Range (ATR) | 0.17 | 0.34 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 42.57 | 19.75 |
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.